In-Vitro Diagnostics Quality Control Market Snapshot

Key Players

  • Bio-Rad Laboratories Inc. (US)
  • Thermo Fisher Scientific Inc. (US)
  • Abbott Laboratories (US)
  • Siemens Healthineers (Germany)
  • Becton Dickinson and Company (US)
  • Ortho Clinical Diagnostics (US)
  • Sysmex Corporation (Japan)
  • SERACON Diagnostics (Canada)

Market Size

Base Year 2024
$1.56 Bn
CAGR
6.75%
Forecast 2034
$3.00 Bn

Market Segments

By Product
Controls, Calibrators
By Type
Quality Control, Quality Assurance Services
By Manufacturer Type
Third-Party Controls, Independent Controls, Instrument-Specific Controls, OEM Controls
By End Use
Hospitals, Laboratories, Home Care, Others

Market Dynamics

Drivers
  • Increasing prevalence of chronic diseases
  • High demand for laboratory accuracy
Restraints
  • High Competitive Rivalry
  • Stringent Regulatory Policies
Opportunities
  • Rising chronic disease prevalence
  • Increased healthcare expenditure

Market Size

The In-Vitro Diagnostics Quality Control Market was valued at USD 1.66 billion in 2025, and it is projected to increase to USD 2.99 billion by 2034. This growth, marking a Compound Annual Growth Rate (CAGR) of 6.8%, is a reflection of a steadily expanding market over a decade. By 2024, the market already stood at a significant USD 1.56 billion, showing the ground from which this robust growth period started. Regional data from 2024 highlights the distribution of the market, with different global regions contributing varying shares. North America had the most substantial share, contributing 39.3% to the market. Following North America was the Asia Pacific and Europe regions with shares of 29.2% and 24.5% respectively. The regions of Latin America and the Middle East and Africa contributed smaller proportions to the market share, with 3.6% and 3.5% respectively.

Key Takeaways

  • By Product - Controls held the leading share in the segment in 2024.
  • By Type - Quality Control led the market accounting for the majority share in 2024.
  • By Manufacturer Type - OEM Controls were the lead subsegment in the year 2024.
  • By End Use - Hospitals were the top users holding the predominant position in 2024.
in-vitro-diagnostics-quality-control-market market size

Key Driving Factors

Stringent Regulatory Standards for Precise Diagnostic Results

In the in-vitro diagnostics quality control market, a substantial driving factor is the imposition of stringent regulations by health authorities worldwide, including the FDA in the U.S. and the European Medicines Agency in the EU. These bodies mandate precise and reliable diagnostic results to enhance patient safety, putting considerable emphasis on quality control procedures. As a result, IVD manufacturers must invest in quality control measures to comply with these standards, driving growth in this market. This development is majorly propelled by authorities' heightened focus on reducing diagnostic errors, which could potentially result in misdiagnosis and improper patient treatment. Consequently, IVD companies are pressured to incorporate robust quality control practices, necessitating more resources allocated towards market offerings related to IVD quality control.

Adoption of Multifaceted IVD Tests due to the Emergence of Individualised Patient Care

A central driving factor shaping the in-vitro diagnostics (IVD) quality control market is the growing adoption of complex IVD tests brought about by the trend towards personalised medicine. With the emergence of precision healthcare approaches, there's an increasing demand for sophisticated genetic and molecular diagnostic testing. These tests, being more complex, require superior quality control methods to validate their accuracy and reliability. As medical practitioners strive to provide individualised care using detailed personal health profiles, popularity of these advanced diagnostic tests has surged, consequently bolstering demand in the IVD quality control market. This shift towards comprehensive patient profiling and individual specific diagnostic approaches underscores the critical need for high-quality, reliable test results, hence stimulating expenditures in IVD quality control.

Market Evolution by Timeline

2019-2023
In this period, many large pharmaceutical companies focused on bringing in-vitro diagnostics (IVD) control products to various hospitals and labs across North America and Europe. Value-based healthcare model standards favored IVD control market as they enhanced patient outcomes. Forced by FDA's regulatory system and European Union's In-Vitro Diagnostic Regulation (IVDR), developers tightened control standards, posing both opportunities and challenges. Flat rate, long-term contracts with suppliers were the prevailing business model, ensuring consistent supply and quality. One of the main risks involved was the stringent regulatory frameworks that demanded substantial investment in quality control.
2024
In 2024, main regions of demand were North America, Europe, and increasing interest from Asia. The Chinese government's initiative towards enhancing healthcare standards boosted demand. IVD providers primarily used a subscription-based model, comprised of maintenance and service-level agreements. FDA and European standards continued to drive control requirements whilst also encouraging use of automation in IVD control. This year, the major risk was supply-chain disruption, largely due to the raw material shortage caused by global trade restrictions.
2025-2029
During this period, the Africa & Middle East regions got into focus due to initiatives such as the United Nations' Sustainable Development Goals. Companies experimented with pay-per-use models, which allowed for cost-effective diagnostics in lower-income regions. This was also fueled by robust advancements in microfluidic technologies for IVD. Continuous growth in mobile health technologies promoted remote management of IVD devices. A prominent regulatory event was WHO's Essential Diagnostics List revision, greatly impacting the IVD control demand pattern. The major risk here was infrastructural development in emerging markets posing challenges.
2030-2034
Global demand for IVD quality controls persisted with a rise in chronic diseases. Keeping increasing complexity in mind, suppliers introduced artificial intelligence, simplifying the IVD control process. The adoption of International Organization for Standardization (ISO) 15189 standards related to quality and competence in medical labs impacted the technology and policy. A mix of contract types including master service agreements and annual subscription contracts was trending. Risks included uncertainty around healthcare policy changes amongst different regions, likely due to changing governmental regulations and global health challenges.

Future Market Outlook

Technology Trends

The In-Vitro Diagnostics (IVD) Quality Control market is experiencing a notable emphasis on automation and digitization, evidenced by the advancements introduced by companies like Roche in 2022 with their Cobas 5800 system, which integrates automated processes for enhanced efficiency in laboratory settings. A growing trend is the adoption of real-time monitoring systems, as seen in Abbott's initiatives in 2023 to implement quality control solutions that utilize digital platforms to track device performance. The involvement of regulatory bodies, such as the U.S. Food and Drug Administration (FDA), has spurred the implementation of stringent quality control standards, which companies must align with to ensure compliance. In 2021, the International Organization for Standardization published ISO 15189, emphasizing the importance of quality management in medical laboratories, influencing product development in this space. The rise of personalized medicine is further pushing for rigorous quality control measures, as exemplified by Genomic Health’s focus on precision testing since 2020, necessitating robust validation processes. Additionally, data analytics tools are becoming increasingly prevalent in the market; for instance, Siemens Healthineers launched an upgraded analytics platform in 2023 that aids laboratories in optimizing quality control protocols. The combination of these technology trends illustrates a transition towards more interconnected and efficient systems designed to enhance the reliability of in-vitro diagnostic products across the global landscape.

Future Opportunities

The global IVD Quality Control market presents significant opportunities as compliance requirements continue to evolve, particularly in regions like Europe, where the In-Vitro Diagnostic Regulation (IVDR) took effect in May 2022, ushering in stricter guidelines for manufacturers. Companies are likely to seek partnerships and collaborations to navigate these regulatory complexities, similar to the collaboration between Bio-Rad Laboratories and Stata in 2023, aimed at improving control solutions. The increasing emphasis on point-of-care testing is opening avenues for the development of quality control products that cater to decentralized environments; for instance, the rise of at-home testing kits following the COVID-19 pandemic has sparked innovation. Another opportunity lies in the integration of artificial intelligence for quality control processes, with companies such as Ortho Clinical Diagnostics exploring AI-driven solutions to improve accuracy and efficiency. The focus on sustainability is another notable trend, as seen in Thermo Fisher Scientific's 2023 initiative to reduce waste in the manufacturing of quality control products by utilizing eco-friendly materials. Furthermore, the growing importance of biobanking and specimen management, highlighted by initiatives from the National Institutes of Health in 2022, is driving demand for quality controls tailored specifically for longitudinal studies. These evolving trends signify a future where quality control in IVD is increasingly aligned with broader healthcare innovations and regulations worldwide.

Segmentation Analysis

By Product

The market is divided into subsegments including Controls and Calibrators, among which, Controls accounted for the largest revenue share while Calibrators are expected to grow at the fastest CAGR during the forecast period.

Largest Revenue Share

Controls

Market Share Leader

Controls had the largest revenue share in the market, which can be attributed to several factors. For instance, market demand for reliable and high-precision products has led to increased adoption of controls. Similarly, the complexity of modern systems calls for a more refined regulatory environment compelling better quality checks. Importantly, controls are considered critical contributors to efficiency, stability, and accuracy of systems leading to widespread implementation across a variety of sectors, including industrial, residential, and commercial. Geographically speaking, advanced regions with robust technological infrastructure contribute significantly to the revenue of the controls subsegment. Customer preferences for technologically sophisticated systems have led to greater adoption of controls, fuelling market growth. Moreover, high switching costs often make it more economical for customers to maintain their commitment to controls instead of opting alternatives. Finally, strong distribution channels, including online sales and direct-to-customer provisions, have made controls more accessible, thus boosting revenue.

Fastest CAGR

Calibrators

Forecast Period Growth Leader

Despite representing a smaller revenue share presently, Calibrators are predicted to grow at the fastest CAGR forecast period. A range of drivers can be delineated for this positive trend. Technological catalysts, particularly advancements in sensor technology and software integration allow calibrators to achieve greater system harmonization and increase overall efficiency. Adopters often find calibrators instrumental in reducing labor costs and brave their high initial capital expenditure. Legislative push for better quality control can be expected to drive the growth of the Calibrators subsegment. However, barriers to adoption cannot be ignored. The initial implementational complexities and costs may dissuade smaller entities from immediate adoption. Meanwhile, prospective collaborations with market-leading firms may serve to ameliorate market barriers. In the near-term, shifts in technology or regulatory environment present risks to the Calibrators subsegment. In sum, despite any present hurdles, the outlook for calibrators remains promisingly strong.

By Type

The market is divided into subsegments including Quality Control and Quality Assurance Services. Quality Control accounted for the largest revenue share while Quality Assurance Services is expected to grow at the fastest CAGR during the forecast period.

Largest Revenue Share

Quality Control

Market Share Leader

Quality Control leads in terms of revenue because of its critical role in the product manufacturing sector. Businesses across all industries, especially in manufacturing and food production, rely on quality control measures to ensure their product meets established standards, thus ensuring customer satisfaction and trust. Key drivers for this segment are stringent regulatory requirements, globalization of manufacturing processes, and the quest for operational excellence. These drivers lead to a demand surge, especially in regions with robust manufacturing sectors such as Asia and North America. Other factors contributing to its high revenue include complex supply chains requiring stringent control mechanisms, the shift towards automation, and the increase in outsourcing of quality control services. In addition, purchasing decisions are often driven by regulatory compliance and the capability of the quality control service to mitigate risk, leading to high switching costs and steady revenue for this subsegment.

Fastest CAGR

Quality Assurance Services

Forecast Period Growth Leader

Quality Assurance Services is projected to witness the fastest growth, driven by the growing realization of its foundational importance in the entire product lifecycle. Technological advancements have led to a more proactive, real-time quality assurance model, replacing the old, reactive model. This shift presents a significant growth opportunity. Moreover, due to increasing regulatory complexities, businesses are turning to QA services for assistance in navigating the regulatory landscape. Demand is fueled capital expenditure in sectors such as pharmaceuticals and automotive, where QA is fundamental to product reliability and safety. Partnerships between QA service providers and businesses, across different sectors, also catalyze growth. However, adoption barriers such as reluctance to change and perceived high costs may pose challenges in the short term. With the right strategies, these barriers can be turned into growth catalysts.

By Manufacturer Type

The market is divided into subsegments including Third-Party Controls, Independent Controls, Instrument-Specific Controls, and OEM Controls. In the base year 2024, OEM Controls accounted for the largest revenue share while Third-Party Controls is expected to grow at the fastest CAGR during the forecast period.

Largest Revenue Share

OEM Controls

Market Share Leader

OEM Controls has been leading in market revenue in 2024 owing to a series of factors predominantly driven by the business model which proves profitable for both manufacturers and end customers. Original Equipment Manufacturer controls get directly integrated into the end product, offering consistency and reliability in terms of quality, thereby providing a competitive advantage to the product manufacturer. Also, by building the controls as an integral part of their product, manufacturers can ensure optimum performance and potentially increase the lifespan of their product. This results in substantial demand for OEM controls across a range of industries such as automotive, machinery, consumer electronics, among others. In addition to this, OEM controls often come with warranties that ensure after-sales service, thereby creating high customer retention and a continual revenue stream. On a geographic scale, Asia-Pacific region, being a major hub of OEMs, largely contributes to this segment's revenue.

Fastest CAGR

Third-Party Controls

Forecast Period Growth Leader

While OEM Controls lead in the revenue sector, Third-Party Controls are expected to register the fastest growth rate. The key growth drivers for this segment can be attributed to the increased flexibility, cost-effectiveness, and rapid technological evolution. Third-party controls offer manufacturers a way to bypass the constraints that may be associated with using only original equipment manufacturer components, and thus can adapt quickly to changes in technology or industry standards. They also offer competitive pricing models, making them an attractive option for businesses seeking to minimize expenses. However, the adoption of third-party controls faces barriers such as compatibility issues, quality concerns, and the risk of voiding warranties for the existing systems. Widespread digitalization, easing of regulation, and the formation of strategic partnerships are triggering an increase in the adoption of third-party controls, driving the segment's growth. The growth risk remains in the form of technology failures or stricter policies imposed.

By End Use

The market is divided into subsegments including Hospitals, Laboratories, Home Care, and Others. Hospitals accounted for the largest revenue share while Home Care is expected to grow at the fastest CAGR during the forecast period.

Largest Revenue Share

Hospitals

Market Share Leader

Hospital settings contribute the most to revenue in this segment. The primary driver for this scenario is the high patient influx coupled with the advanced facilities and services these institutions provide, which are often beyond the capabilities of other end-users like home care and laboratories. Hospitals are usually better equipped with sophisticated medical technologies, and capable of providing a wide range of services, from standard medical procedures to complex surgeries. Further, hospitals tend to be the default choice of preference for critical care patients and emergency situations. The general perception of hospitals offering higher quality care also plays a role in driving revenue. Moreover, many hospitals are shifting towards a value-based care model that is predicted to foment increased patient volume. Geographically, developed urban regions with high population density contribute significantly to this segment due to the presence of large, well-equipped hospitals.

Fastest CAGR

Home Care

Forecast Period Growth Leader

Home care, although currently not the leading segment in terms of revenue, holds the potential for rapid CAGR, surpassing other subsegments. The primary growth drivers include technological advancements, shift in preference towards home care services due to convenience and cost, and increasing demand for personalized care. Elderly population and patients with chronic illnesses requiring long-term care are increasingly preferring home-based services due to perceived comfort and improved patient outcomes. Technological advancements in telemedicine and remote patient monitoring are making home care more viable and accessible, contributing to its growth. However, adoption barriers for this segment include regulatory hurdles and fragmentation in service delivery. Policies encouraging individual care and partnerships amongst tech companies and healthcare providers can act as catalysts in overcoming these barriers. The increased utilization of digital health platforms has also supported the growth of this segment. Nonetheless, near-term risks such as data security and privacy can potentially hinder the growth.

Competitive Analysis

Key Market Players

Manufacturers / OEMs

BIO-RAD LABORATORIES INC.
US
Thermo Fisher Scientific Inc.
US
Randox Laboratories Ltd.
UK

Key Suppliers & Raw Materials

Abbott
US
Roche Diagnostics
Switzerland
Siemens Healthcare Private Limited
Germany

Distributors, Integrators & Channel Partners

Danaher Corporation
US
Henry Schein, Inc.
US
McKesson Corporation
US

Porter’s Five Forces Analysis

This is an examination of the competitive forces in the In-Vitro Diagnostics Quality Control Market.

Supplier Bargaining Power

High

Limited suppliers of specialized reagents increase their bargaining power.

Buyer Bargaining Power

Low

Buyers often form long-term partnerships with suppliers reducing their bargaining power.

Threat of Substitutes

Low

Low threat due to stringent regulatory approval processes for alternative products.

Threat of New Entrants

Medium

Regulatory barriers and high R&D expenses pose a moderate entry barrier.

Competitive Rivalry

High

Intense competition among established companies with significant market shares.

Regional Analysis

Geographic market dynamics and growth opportunities across key regions

Global Market Outlook

in-vitro-diagnostics-quality-control-market market regional share

North America

In 2024, the North American In-Vitro Diagnostics Quality Control Market was characterized by stringent regulations and advancements in technologies, with demand primarily being driven by the healthcare sector. Key drivers include an increase in disease prevalence and aging population in the U.S, Canada, and Mexico, prompting broader utilization of diagnostic testing. Stringent regulatory standards, such as FDA's IVDR, necessitated robust quality control in diagnostic devices, promoting market growth. Furthermore, growing investment in research and development expanded technological capabilities, supporting the adoption of advanced quality control methods.

Consumers in this market exhibited a shift towards personalized medicine, stimulating the need for precision diagnostics and subsequent quality control. The convergence of AI and diagnostics led to novel product offerings like digital solutions for better quality assurance. There were significant partnerships and mergers among key players aiming to leverage shared resources for improving diagnostic quality control standards. For instance, enterprise-level diagnostic manufacturers increasingly collaborated with healthcare facilities for field testing. Regulatory bodies enforced more rigorous scrutiny of quality compliance, influencing manufacturers to invest more heavily in the quality assurance aspect of their products. This purchase behavior represented a market trend in these regions, reflecting consumers' growing awareness of quality assurance in in-vitro diagnostics.

Asia Pacific

In 2024, the In-Vitro Diagnostics Quality Control Market in Asia Pacific witnessed significant growth, attributed to several drivers and trends. Increased investment in healthcare infrastructure, especially in developing nations like India and China, positively impacted market dynamics. Robust policies were implemented to ensure quality control, particularly in Australia and Japan, spurring the requirement for advanced diagnostic tools. Additionally, the expedited adoption of innovative diagnostic technologies by laboratories and healthcare facilities across the region affirmed market expansion. A trend towards patient self-testing, stimulated by the desire for convenience, altered buyer behavior. Importantly, manufacturers adapted to this shift by devising home-friendly diagnostics kits, a notable product development strategy in 2024. Furthermore, several Asian companies formed alliances to boost research and technology development in the diagnostic domain, expediting the sector's growth. Enhanced regulation enforcement was observed in key ASEAN markets where governmental bodies rigorously monitored the quality of diagnostic services provided.

Key customers comprised enterprise-level diagnostic laboratories, government healthcare agencies, and large-scale hospitals, particularly in extensive markets like China and India. The retail sector also played a sizable role, specifically in the sale of self-testing diagnostic kits, a trend more pronounced in developed nations such as Japan and Australia. This scenario unveiled a promising picture for the in-vitro diagnostics quality control market in the Asia Pacific region in 2024.

Europe

In 2024, Europe's in-vitro diagnostics quality control market was defined by burgeoning demand, stringent regulations, and burgeoning adoption of advanced technologies. Its enlargement was propelled by a rising prevalence of chronic diseases and an escalating necessity for early diagnosis increasing the demand for sophisticated diagnostic equipment. For instance, conditions like diabetes and cancer were prevalent across nations such as the UK, Germany, and France. Regulatory bodies imposed stringent rules mandating regular quality control assorted IVD tests, pushing manufacturers to ensure reliability and accuracy. Investments in healthcare services and infrastructure, particularly in Central and Eastern Europe, broadened the market. The adoption of cutting-edge technologies, particularly AI-driven diagnostic solutions, underscored supply dynamics.

Emerging trends in this market included the rise of personalized medicine, increased R&D investments, and the implementation of automation. Demand for personalized medicine was particularly strong in settings like Germany, leading to a renewed focus on individualized diagnostic solutions. Companies invested increasingly in R&D to curate test kits that could provide accurate diagnosis in minimal time scales. Automation in the field of in-vitro diagnostics quality control - for instance, robotic process automation and AI-backed quality checks - was particularly observed in enterprise and healthcare sectors across nations like France, Spain and the Nordics. It streamlined processes, mitigated human errors, and improved overall efficiency.

Latin America

In 2024, the In-Vitro Diagnostics Quality Control market in Latin America (LATAM) witnessed noteworthy advancements. Demand factors such as the increase in healthcare awareness and a substantial rise in infectious and chronic diseases in countries such as Brazil, Mexico, and Argentina undeniably drove the market. Regulations in LATAM, particularly the RDC No. 16/13 in Brazil and NOM-007-SSA3-2011 in Mexico, shaped the sector by mandating strict IVD quality control. Furthermore, countries like Colombia and Chile experienced a surge in diagnostic laboratory investment, strengthening the infrastructure for IVD QC adoption. However, supply constraints partially offset this trend due to limited regional manufacturing capabilities.

Several trends have been key. For instance, there was a palpable shift towards the use of molecular and microbiology controls, specifically in Peru's healthcare sector. Cross-border partnerships, notably between Brazilian and Mexican biotech companies, became commonplace, working to diverse and improve product offerings. Increased policy enforcement around IVD quality standards in the region was observed, mainly driven by Argentina’s National Administration of Medicines, Food and Medical Technology (ANMAT). Notably, digital solutions - for example, online purchase of IVD controls - gained traction amongst healthcare providers in most LATAM markets, due to their convenience and cost-effectiveness.

Middle East & Africa

In 2024, the In-Vitro Diagnostics (IVD) Quality Control Market witnessed significant growth in the Middle East and Africa due to various key drivers and trends. Increased healthcare investment boosted the demand for quality control services, particularly in Saudi Arabia and the United Arab Emirates, where their governments prioritized healthcare infrastructural development. Strict regulatory environments in Israel and South Africa also fueled the need for IVD Quality Control, ensuring accurate and reliable test results. Furthermore, technological adoption across multiple nations, including Qatar and Egypt, streamlined IVD Quality Control processes, making them time-effective and cost-efficient. Trends that emerged in this year revolved around buyer behavior and technology transitions. A rise in awareness about IVD amongst healthcare professionals in Nigeria and Kenya led to increased adoption rates.

Product shifts were evident too, with the introduction of advanced controls offering multi-analyte panels. Partnerships played a crucial role in growing the market, the most noticeable being collaborations between IVD manufacturers and local healthcare providers. Israel led in enforcing stringent quality control policies which served as a blueprint for other countries including Saudi Arabia. Bearing the brunt of these shifts were sectors like healthcare and manufacturing. In particular, hospitals, diagnostic laboratories, financial services, and IVD manufacturers actively participated in adopting both the technological advancements and regulatory changes.

Recent Industry Developments

Latest market innovations, product launches, and strategic initiatives

July 2026

bioMérieux launched GENE-UP® PROBIOTIC SPECIES ID, a first-of-its-kind commercialized species-level identification PCR solution for in-house quality control teams and external laboratory partners in dietary supplements manufacturing.

March 2025

Siemens Healthineers announced a strategic partnership with Randox Laboratories to co-develop and distribute standardized quality control materials for molecular diagnostics, aiming to harmonize QC across platforms.

Frequently Asked Questions

Recent Blogs

Key Strategies for Manufacturers to Capitalize on the Energy Storage Systems Market
Updated: Oct 28, 2025
VIEW
Navigating the Advanced Composites Market: A Comprehensive Guide for Suppliers and Distributors
Updated: Oct 28, 2025
VIEW
Decoding the Impact of Government Policies on the Global Electric Vehicle Market
Updated: Oct 28, 2025
VIEW

Recent News

Shandi Global Introduces ‘Chanza’ in India, Targeting High-Volume Foodservice and Institutional Nutrition Demand
Published: Oct 28, 2025
VIEW
Air Liquide Expands Its Presence in India With the Acquisition of NovaAir
Published: Oct 28, 2025
VIEW
Samsung Introduces 2025 Bespoke AI Appliance Lineup in India, Featuring Bespoke AI Laundry Combo
Published: Oct 28, 2025
VIEW